tbuckley/cabot-search huggingface dataset:
Abstract 4620: Development of orthotopic breast cancer brain metastasis patient-derived xenograft(PDX) model
Authors: Masanori Oshi
Journal: Cancer Research (2019)

Abstract Background: The vast majority of the mortality of breast cancer results from distant metastasis and pre-clinical models are in critical need for effective drug development. Patient-derived xenograft (PDX) maintains the features of the donor tumors such as intra-tumor heterogeneity; however, PDX model of breast cancer brain metastasis that delivers stable consistent results is not popularized. We demonstrate our novel methods (coined “Oshi”method) used to develop an orthotopic brain metastasis patient-derived xenograft model (PDMOX) for breast cancer brain metastasis via tumor tissue implantation. Methods: Brain metastasis PDX were created using metastatic brain tumors from breast cancer patients and implanting them in the brain of NSG female mice. Tumors of ~1 mm3 were implanted mechanically minced tissue with medium. We implant the tissue through a frontal bone burr hole into the right caudate putamen. Tumor growth was monitored by magnetic resonance imaging (MRI). Results: “Oshi” method utilizes a pipette tip in order to inoculate tumor at the same depth. A minced tumor was instilled using a 23G needle as the “non-oshi” method. One hour post-surgical survival after implantation of minced tumor by “non-oshi” method was only 37.5% (3/8), whereas 100% (40/40) by the “Oshi” method. All tumors were well engrafted in surviving mice after both methods. There was larger variation in tumor growth after “non-oshi” (Median 20±25.0 day, range: 12-24 day. Tumor volume: median 5.6±21.0 mm3, range 2.8-48.7 mm3). One mouse developed ptosis, and 2 out of 3 mice that underwent the “non-oshi” method had sudden death. On the other hand, all mice that underwent the “Oshi” method lived until the tumor grew to 125-200 mm3 without neurological symptoms. The engraftment rate of Mincing tumor were 100% at 1.5 months after implantation, while the engraftment rate of Enzymatic digestion tumors was only 50% at 2 months. Mincing tumor had faster growth speed than the tumor of enzymatic digestion. The engraftment time of enzymatic digestion tumor was slower than other tumor tissue forms. All 3rd generation tumors could be detected at the point of 1month after implantation, on the other hand, it took 2 month to detect 1st generation tumors. The growth of 3rd generation tumors was significantly faster and bigger than others. Conclusion: Various surgical techniques used to generate PDMOX breast cancer models showed major differences in the tumors and outcomes. These novel models are expected to become powerful tools for preclinical studies in metastatic breast cancer. Citation Format: Masanori Oshi. Development of orthotopic breast cancer brain metastasis patient-derived xenograft(PDX) model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4620.
Reply
Authors: Osamah J. Saeedi, Tobias Elze, Loris D’Acunto, Ramya Swamy, Vikram Hegde, Surabhi Gupta, Amin Venjara, Joby Tsai, Jonathan S. Myers, Sarah R. Wellik, Carlos Gustavo De Moraes, Louis Pasquale, Lucy Q. Shen, Michael V. Boland
Journal: Ophthalmology (2019)
Instructions to Authors
Journal: Circulation Research (1973)

manuscripts that present the results of significant research on the cardiovascular and the renal systems.First priority is given to unpublished research that provides better understanding of mechanisms that influence normal or abnormal cardiovascular-renal function.The research may be in the field of biology, biochemistry, biophysics, clinical medicine, genetics, immunology, morphology, pathology, pharmacology, physiology, or theoretic biology-or it may be interdisciplinary.Lower priority is given to reports that merely confirm published work, that present a new method or a modification of an existing method without applying it to a biologic problem, or that are preliminary or incomplete.
TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).
Authors: Neeraj Agarwal, Neal D. Shore, Curtis Dunshee, Lawrence Ivan Karsh, Beth Sullivan, Nicola Di Santo, Mohamed Elmeliegy, Michelle Casey, Ruben G.W. Quek, Akos Czibere, Karim Fizazi
Journal: Journal of Clinical Oncology (2019)

TPS337 Background: ENZA is approved to treat men with CRPC. TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP1/PARP2 and traps PARP on DNA, preventing DNA damage repair (DDR), and causing cell death in BRCA1/2-mutated cells. TALA is approved in the US to treat germline BRCA1/2-mutated HER2- locally advanced/metastatic breast cancer. A combination of TALA with ENZA in mCRPC may improve clinical outcomes. Methods: Eligible patients (pts) in parts (P) 1 and 2 of this study are aged ≥18 years; have asymptomatic/mildly symptomatic mCRPC, ECOG PS ≤1, and no brain metastases; and have not received taxanes/novel hormonal therapy (NHT). P1 is an open label study to confirm the starting dose of TALA to be given in combination with ENZA. P2 is a randomized double-blind study that will evaluate the safety, efficacy and pt reported outcomes of TALA (0.5 mg QD) + ENZA (160 mg QD) vs placebo + ENZA in 2 cohorts (C). C1: pts with mCRPC (all comers) (N = 560); C2: pts with DDR gene mutations likely to sensitize to PARP inhibition (DDR deficient) (N = 300). Randomization will be stratified by prior treatment with NHT for castration sensitive prostate cancer (CSPC) or prior treatment with taxane-based chemotherapy for CSPC (yes/no), and DDR mutation status (deficient vs. nondeficient/unknown). For P1, the primary endpoint is safety; the secondary endpoint is pharmacokinetics of TALA and ENZA. For P2, the primary endpoint is radiographic progression-free survival (rPFS), defined as time to progression in soft tissue per RECIST v1.1 or in bone per PCWG3 criteria or death and evaluated separately in all comers (C1) and DDR-deficient (DDR-deficient pts from C1 and C2 combined, N = 380 pts) populations. The key secondary endpoint is overall survival. Efficacy will be assessed by radiography every 8 weeks up to week 25 and every 8-12 weeks thereafter. P2 analysis for rPFS is powered at 90% and 85% using a 2-sided log-rank test with alpha of 0.025, respectively, in the all comers and DDR deficient populations. This study was sponsored by Pfizer Inc. Clinical trial information: NCT03395197.
Annual Report of the Supervising Surgeon-General of the Marine-Hospital Service of the United States for the Fiscal Year 1888
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE JOURNAL AND THE ASSOCIATION.
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical News
Journal: JAMA (1905)

<h3>ILLINOIS.</h3><h3>Facilities for State Health Board.</h3> —The appropriations of the State Board of Health have been materially increased by the present general assembly. Funds for a state laboratory and a registrar of vital statistics have been granted. <h3>Appropriations for Asylums.</h3> —The legislature has appropriated $380,600 for the maintenance of the Illinois Western Hospital for the Insane, Watertown, for the next biennium. —The appropriation for the Illinois Eastern Hospital for the Insane, Kankakee, was cut to $154,000. <h3>Fire at State Hospital.</h3> —A fire at the Illinois Southern Hospital for the Insane, Anna, damaged the power-house to the extent of $5,000. No casualties occurred, but the patients, as a matter of precaution, were taken from their rooms and marshalled in halls in case it proved necessary to remove them from the building. <h3>Legislative Status.</h3> —Seven osteopathic bills have been introduced in the general assembly during the present session. One of these is
An RNA Interference Model of RPS19 Deficiency in Diamond Blackfan Anemia Recapitulates Defective Erythropoiesis and Rescue by Dexamethasone: Identification of Dexamethasone Responsive Genes by Microarray.
Authors: Benjamin L. Ebert, Michele Lee, Jennifer Pretz, Todd R. Golub, Colin Sieff
Journal: Blood (2004)
Reply
Authors: A. Selcuk Adabag, Barry J. Maron, Evan Appelbaum, Caitlin J. Harrigan, Jacqueline L. Buros, C. Michael Gibson, John R. Lesser, Constance A. Hanna, James E. Udelson, Warren J. Manning, Martin S. Maron
Journal: Journal of the American College of Cardiology (2008)
JAMES THACHER (1754-1844) PATRIOT, HISTORIAN, BIOGRAPHER
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of Intravenous Mannitol in Postperfusion Oliguria-Anuria
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Compend OF General Pathology.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The management of cancer pain
Authors: N. I. Cherny, R. K. Portenoy
Journal: CA A Cancer Journal for Clinicians (1994)

Surveys indicate that clinicians are frequently ill equipped to treatcancer pain. Pain is often poorly assessed, and many caregivers lacksufficient knowledge to optimize treatment. Effective management requiresan understanding of pain pathophysiology, the ability to identify andevaluate pain syndromes, and familiarity with proven therapeuticstrategies. Opioid pharmacotherapy is the mainstay of treatment. Practicalaspects of opioid therapy include selection of both drug and route, dosetitration, and management of side effects. Specific strategies for themanagement of patients who are unable to attain an acceptable balancebetween pain relief and side effects include both noninvasive interventions (such as adjuvant analgesics, psychological therapies, and physiatrictechniques) and invasive interventions (such as the use of intraspinalopioids, neural blockade, and neuroablative therapies). Sedation is anoption at the end of life for the treatment of pain that is refractory toother interventions. These approaches can provide adequate relief to thevast majority of patients, most of whom will respond to systemicpharmacotherapy alone. Patients with refractory pain should have access tospecialists in pain management or palliative medicine.
Age and Sensitivity to Lead Toxicity: A Review
Authors: Edward B. McCabe
Journal: Environmental Health Perspectives (1979)

During the past 20 years considerable attention has been focused on the epidemiologic features of childhood lead poisoning in the United States. Large numbers of children with symptomatic intoxication, as well as those with incipient symptoms, were commonplace a decade ago for physicians working in inner-city hospitals. With the recent availability of improved screening techniques, as well as a variety of environmental control measures, the incidence of symptomatic lead poisoning in children has diminished significantly in recent years. With the focus shifting from children with dangerously elevated body lead burdens to those with less significant exposures, increased attention has been directed to the various inherent metabolic and physical characteristics of the young that may influence the toxic effects of lead exposure. A number of differences with respect to lead exposure, absorption and retention, and varying nutritional conditions between children and older individuals are discussed. Experimental studies dealing with age differences of lead-treated animals are examined, and relevant human studies are reviewed.
EXPERIMENTAL STREPTOCOCCUS ARTHRITIS IN RELATION TO THE ETIOLOGY OF ACUTE ARTICULAR RHEUMATISM.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association between renal function and chemotherapy-related toxicity in older adults with cancer.
Authors: Lindsay Leuthen Peterson, Arti Hurria, Tao Feng, Supriya Gupta Mohile, Cynthia Owusu, Heidi D. Klepin, Cary Philip Gross, Stuart M. Lichtman, Ajeet Gajra, Ilya G. Glezerman, Vani Katheria, Laura Zavala, David D. Smith, William P. Tew
Journal: Journal of Clinical Oncology (2015)

9509 Background: Older adults with cancer are at increased risk for chemotherapy-related toxicity (CRT). Tools are needed to better define their risk and aid in treatment planning. Renal function declines with age and can be calculated with various formulas, although the ideal formula for such calculations is unclear. We therefore evaluated the association between renal function and CRT in older adults and compared the effect of different renal function formulas and body weight measurements on this association. Methods: This is a secondary analysis of data from a prospective multicenter study of 500 patients age 65 and older who were starting a new chemotherapy regimen. Renal function was estimated with four formulas (modified Jelliffe [Jelliffe], Cockcroft-Gault [CG], Wright, and Modification of Diet in Renal Disease [MDRD]), using actual, ideal and adjusted body weights. The association between baseline renal function and grade 3-5 CRT was evaluated by unconditional logistic regression. Results: Mean age of the 492 evaluable patients was 73 (range 65-91); 40% were aged ≥ 75 years (18% age 80-91); 61% had stage IV disease; 56% were female. Mean estimated renal function ranged from 56 to 78 mL/min, depending on the formula. One or more grade 3-5 toxicities occurred in 53% of patients (26% hematologic; 43% non-hematologic). Decreased creatinine clearance [CrCl] calculated by CG (actual body weight) was associated with increased odds of CRT (OR 1.12, P < 0.01 95% CI 1.04-1.20); for every 10 mL/min decrease in CrCl, the odds of CRT increased 12%. This association is independent of the type of chemotherapy received (renally cleared vs not). Neither primary dose reduction nor chemotherapy duration was associated with CRT. There were no statistically significant associations between decreased renal function with non-CG formulas (Jelliffe, Wright and MDRD) and odds for CRT. Serum creatinine alone was not associated with toxicity risk (OR 0.67, P = 0.15 95% CI 0.37-1.14). Conclusions: Decreased CrCl (as measured by CG with actual body weight) is associated with increased odds of chemotherapy-related toxicity and should be considered when treating older adults with cancer. Serum creatinine alone is not adequate for risk assessment.
Nouveau Traité de Psychologie
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapeutic choices not always predictable
Authors: Barbara Bolsen
Journal: JAMA (1982)

A symposium on medical technology held during the recent meeting of the American Association for the Advancement of Science (AAAS) in Washington, DC, brought forth some new and somewhat surprising information. For example, when evaluating the use of different therapies in clinical practice, patient values must be considered. Thus, some patients, when choosing between two therapies for the same condition, prefer treatment that prolongs life but compromises its quality, while others prefer the opposite, said Barbara J. McNeil, MD, PhD, associate professor of radiology, Harvard Medical School, Boston. She cited a study of healthy firefighters and business executives, in which 8% of the firefighters and 24% of the executives, confronted with a hypothetical situation involving cancer of the larynx, chose treatment that would preserve their ability to speak at the expense of lengthened survival (<i>N Engl J Med</i>1981;305:982-987). But "the medical profession has decided that this is the column